Translate Bio Inc

Translate Bio — Technical Presentation (August 2020)

8 slides from Translate Bio's technical presentation, Aug 25, 2020

  1. Slide 1: Sanofi Pasteur COVID-19 Vaccine Programs

    Exhibit 99.1 Sanofi Pasteur COVID-19 Vaccine Programs John W. Shiver, Ph.D., Global R&D Head, Sanofi Pasteur ISV Aug 25, 2020 mRNA presentationExhibit 99.1 Sanofi Pasteur COVID-19 Vaccine Programs John W. Shiver, Ph.D., Global R&D Head, Sanofi Pasteur ISV Aug 25, 2020 mRNA presentation

  2. Slide 2: Sanofi's Two COVID-19 Vaccine Approaches

    Sanofi’s Two COVID-19 Vaccine Approaches 1 2 Baculovirus mRNA recombinant vaccine Platform + (2) vaccine approach (1) Protein mRNA approach mRNA Adjuvant Antigen Formulation (1) • Licensed recombinant platform • Innovative approach • Existing large scale capacity • Significant existing investment in

  3. Slide 3: mRNA Vaccine Approach to address COVID-19 Pandemic

    mRNA Vaccine Approach to address COVID-19 Pandemic messenger RiboNucleic Acid (mRNA) + Lipid NanoParticle (LNP) mRNA vaccine approach • Deliver mRNA packaged in LNP to the human cell. • The cell’s own machinery is used to translate the mRNA in vitro LNP into protein. Transcription mRNA-LNP mRNA Form

  4. Slide 4: SARS-CoV-2 mRNA Sequence Design

    SARS-CoV-2 mRNA Sequence Design Full-length pre-fusion stabilized SARS-CoV-2 Spike Protein Structure GSAS PP S1/S2S2’ SS RBD HR1 CD TM NTD SD1 SD2 FP CH HR2 CT QTNSPRRARSVAS SRLDKVEAE 982 SS – Signal Sequence 677 689 990 NTD – N-Terminal Domain RBD – Receptor Binding Domain SD1 – Subdomain 1 SD2 – S

  5. Slide 5: mRNA Vaccine Technology

    mRNA Vaccine Technology NON-LIVE SAFETY IMMUNOGENICITY MANUFACTURING • Induces potent • In vitro transcription • RNA does not • No live pathogens humoral and cell- • No cell culture integrate into the • Sequence specificity mediated immune host genome and • Scalable to large responses • Flexible pro

  6. Slide 6: Humoral Immunogenicity of CoV2 mRNA/LNP Vaccine in Cynomolgus Monkeys

    Humoral Immunogenicity of CoV2 mRNA/LNP Vaccine in Cynomolgus Monkeys Induction of Robust Binding and Neutralizing Antibody Activities SARS-CoV2 ELISA vs pre-S dTM 4 Microneutralization 10 3 10 2 10 1 10 0 10 Timepoint (d) -4 14 21 28 35 42 -4 14 21 28 35 42 -4 14 21 28 35 42 -4 14 21 28 35 42 Day D

  7. Slide 7: T Cell Immunogenicity of CoV2 mRNA/LNP Vaccine in Cynomolgus Monkeys

    T Cell Immunogenicity of CoV2 mRNA/LNP Vaccine in Cynomolgus Monkeys Induction of TH1 Biased T cell Response at Day 42 IFNg (TH1) IL-13 (TH2) Peptide Pool: S1 IFNg (TH1) IL-13 (TH2) Peptide Pool: S2 7T Cell Immunogenicity of CoV2 mRNA/LNP Vaccine in Cynomolgus Monkeys Induction of TH1 Biased T cell

  8. Slide 8: Summary

    Summary • SP is developing 2 COVID-19 vaccine approaches that will advance to clinical testing in Sept-Nov 2020; both candidates are manufacturable at scale needed to address the global pandemic. • Two immunizations of SP’s mRNA or adjuvanted recombinant vaccines into non- human primates induce high

Translate Bio — Technical Presentation (August 2020) on 6ix